This report provides comprehensive information on the therapeutic development for Mixed Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Mixed Dyslipidemia Overview
- Therapeutics Development
- Pipeline Products for Mixed Dyslipidemia - Overview
- Pipeline Products for Mixed Dyslipidemia - Comparative Analysis
- Mixed Dyslipidemia - Therapeutics under Development by Companies
- Mixed Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
- Mixed Dyslipidemia Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Mixed Dyslipidemia - Products under Development by Companies
- Mixed Dyslipidemia - Products under Investigation by Universities/Institutes
- Mixed Dyslipidemia - Companies Involved in Therapeutics Development
- Amgen Inc.
- CymaBay Therapeutics, Inc.
- Hanmi Pharmaceuticals, Co. Ltd.
- Matinas BioPharma Holdings, Inc.
- Pfizer Inc.
- Thetis Pharmaceuticals LLC
For more information visit http://www.researchandmarkets.com/research/fpvpqn/mixed